Rhodnius prolixus aggregation inhibitor 1 (RPAI-1), a 19-kDa protein isolated from the salivary gland of R. prolixus, was purified by strong cation exchange and reverse-phase high performance liquid chromatographies. Based on 49 amino-terminal amino acid sequences of RPAI-1, primers were produced to generate probes to screen an R. prolixus salivary gland cDNA library. A phage containing the full-length clone of RPAI-1 codes for a mature protein of 155 amino acids. RPAI-1 shows sequence homology to triabin and pallidipin, lipocalins from Triatoma pallidipennis. The cDNA sequence was cloned in Pet17B Escherichia coli expression vector, producing an active peptide. RPAI-1 inhibits human platelet-rich plasma aggregation triggered by low concentrations of ADP, collagen, arachidonic acid, thromboxane A 2 mimetics (U46619), and very low doses of thrombin and convulxin. Here we show that ADP is the target of RPAI-1 since (i) RPAI-1 inhibits ADP-dependent large aggregation formation and secretion triggered by U46619, without affecting Ca 2؉ increase and shape change; (ii) ADP restored the inhibition of U46619-induced platelet aggregation by RPAI-1, (iii) PGE 1 -induced increase of cAMP (which is antagonized by U46619 in an ADP-dependent manner) was restored by RPAI-1, (iv) RPAI-1 inhibits low concentrations of ADP-mediated responses of indomethacintreated platelets, and (v) RPAI-1 binds to ADP, as assessed by large zone chromatography. RPAI-1 affects neither integrin ␣ 2 ␤ 1 -nor glycoprotein VI-mediated platelet responses. We conclude that RPAI-1 is the first lipocalin described that inhibits platelet aggregation by a novel mechanism, binding to ADP.
Normal hemostasis is initiated when platelets are exposed to subendothelial matrix, where they adhere to collagen via specific cell-surface receptors. This adhesion step is followed by platelet activation that is accompanied by synthesis and release of pro-aggregatory molecules such as TXA 2 1 and ADP, which amplify platelet responses to collagen and recruit additional platelets to the site of injury, respectively (1). The concerted action of collagen, ADP, and TXA 2 activates specific signaling pathways, generating a number of second messengers and leading to the functional expression of integrin ␣ IIb ␤ 3 , the fibrinogen receptor on platelets (1) . Binding of fibrinogen to platelets mediates platelet aggregation, the final common response of activated platelets to most agonists. In addition to platelet aggregation, normal hemostasis involves activation of the blood coagulation cascade and vasoconstriction, making it a very redundant system (2) . Redundancy is also observed in terms of the receptors involved in platelet responses for each specific agonist. It has now become clear that physiologic platelet agonists stimulate platelets by more than one receptor, and specific platelet responses involve distinct receptors. Accordingly, it has been shown that integrin ␣ 2 ␤ 1 receptor mediates platelet adhesion to collagen, whereas GPVI induces most of the signal involved in platelet activation, including phospholipase C␥2 activation by a tyrosine kinase-dependent pathway (3, 4) . The role of additional collagen receptors (e.g. GPIV and P65) remains to be elucidated (5, 6) . On the other hand, thrombin activation of PAR1, but not PAR4, is involved with the formation of the signaling pathway necessary for exposure of negatively charged molecules that increase platelet pro-coagulant activity (7, 8) ; in addition, GPIb and GPV seem to be a positive and a negative modulator of thrombin-induced platelet aggregation, respectively, by a mechanism not fully understood (9) . In the case of ADP, platelets have three distinct receptors as follows: an ionotropic receptor (P2X 1 ) involved with Ca 2ϩ influx; a P2Y 1 -G q protein-coupled receptor that mediates platelet shape change and phospholipase C activation; and a P2Y AC -G i protein-coupled receptor related to inhibition of adenylate cyclase (10, 11) . Activation of both P2Y 1 and P2Y AC receptors is necessary for full platelet activation by ADP (12) (13) (14) . Finally, a number of papers (15) (16) (17) have identified, through binding experiments, two binding sites for thromboxane A 2 (TXA 2 ) in platelets. One site binds TXA 2 mimetics with high affinity and mediates shape change, calcium increase, and cortactin phosphorylation by a G␣ 12/13 -coupled receptor. Another site, of lower affinity, mediates platelet secretion, PKC activation, and platelet aggregation via a G q -coupled TP receptor (18 -21) . U46619-induced platelet aggregation is also modulated by additional molecules released by activated platelets that, in turn, bind to a specific cell receptor such as ADP, epinephrine, and thrombospondin (20 -23) .
Of interest, these pro-hemostatic mechanisms are counterbalanced and regulated by a number of physiologic anti-hemostatic molecules that work in a concerted and redundant manner, including the release of prostacyclin, nitric oxide (NO), and endothelium-dependent hyperpolarizing factor by the endothelium as well as ADP hydrolyzing activity of endothelial cell membrane apyrase (CD39) (24 -26) . In this context, the salivary glands of blood-sucking insects have evolutionarily developed a number of molecules able to counteract the physiologic pro-hemostatic mechanisms that are triggered to avoid blood loss (27) . In most cases, more than one component with distinct anti-hemostatic function has been isolated from the same saliva of blood-sucking insects. In fact, in addition to inhibitors of blood coagulation (28) and vasodilatory molecules (29) , a number of distinct platelet aggregation inhibitors have been described (30) . These molecules include direct collagen inhibitors (31) , inhibitors of platelet adhesion to collagen (32) , apyrases (33) (34) , and catechol oxidases (27) , in addition to thrombin inhibitors (35, 36) , NO-releasing molecules (37) , fibrinogenreceptor antagonists (38) , and specific inhibitors of collageninduced platelet aggregation (39, 40) .
In our previous work characterizing salivary antiplatelet activity from Rhodnius prolixus, we found, by preparative agarose gel electrophoresis, at least three activities inhibiting collagen-induced platelet aggregation. One band was associated with apyrase activity; the second was associated with the major pigmented band (nitrophorins, containing NO) (36, 41) ; and the third was indicative of a basic component by its catodal migration (42) . In this paper, we characterize a novel lipocalin from R. prolixus that inhibits platelet aggregation a new mechanism, binding to ADP.
EXPERIMENTAL PROCEDURES
Materials-R. prolixus were maintained in the Ribeiro laboratory at 27°C and 60% relative humidity. They were offered rabbit blood every 2 weeks through the latex membranes of artificial feeders. Salivary glands of 5th instar bugs starved for 28 -60 days were removed by dissection in groups of 100 pairs, transferred to 1.5-ml conical polypropylene tubes, and stored in 100 l of 10 mM HEPES plus 0.15 M NaCl, pH 7.0 (HEPES/saline, HS), at Ϫ75°C until needed, when they were thawed, disrupted with a small plastic pestle, and centrifuged at 14,000 ϫ g for 5 min. The resulting supernatant was diluted to 2 ml with 50 mM Tris-Cl, pH 8.3, dialyzed (1,000-Da cut-off membrane) against 1 liter of the same buffer overnight (to remove NO), followed by dialysis against water (with several exchanges) for another 24 h to remove salts. Water was obtained with a MilliQ system from Millipore (Bedford, MA). U46619 (9,11-dideoxy-9␣,11␣,11␣-methanoepoxiprostaglandin F 2␣ ), U46069 (9,11- 
-dien-1-oic acid, 9,11,15-trihydroxy-(5Z,8␤,9␣,11␣,13E,15S), and arachidonic acid were from Cayman Chemical (Ann Arbor, MI). [ 3 H]U46619 (9,11-dideoxy-9␣,11␣,11␣-methanoepoxiprostaglandin F 2␣ ) was purchased from Amersham Pharmacia Biotech. ADP, indomethacin, catalase, superoxide dismutase, ascorbic acid, mannitol, and Gly-Pro-Arg-Pro amide were purchased from Sigma. Thrombin was obtained from Calbiochem. Arachidonyltrifluoromethyl ketone was from Biomol (Plymouth Meeting, PA). Collagen, arachidonic acid, and luciferin-luciferase reagent were from from Chrono-Log Corp. (Havertown, PA). Pre-cast 4 -20% polyacrylamide gel and nitrocellulose membranes were from Novex Experimental Technology (San Diego, CA). Sep-Pak C-18 cartridges for solid-phase extraction were purchased from Waters Co. (Milford, MT). Monoclonal anti-phosphotyrosine antibody (PY20) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-rabbit peroxidase-coupled secondary antibody was obtained from Zymed Laboratories Inc. (South San Francisco, CA). Enhanced chemiluminescence (ECL) reagents were from Amersham Pharmacia Biotech. Crotalus durissus terrificus venom was obtained from FUNED (Funda-çã o Ezequiel Dias, MG, Brazil). ␤-Tromboglobulin ELISA kit was purchased from Diagnostica Stago (Les Ulis, France). BCA Protein Assay Reagent was from Pierce. All other reagents including salts were obtained from Merck or Sigma.
High Performance Liquid Chromatography Procedures-Strong cation exchange high performance liquid chromatography was performed on salivary homogenates using a 10 ϫ 250 mm SynChropak S300 column (Micra Scientific, Inc., Northbrook, IL). A CM4100 pump and SM4100 dual wavelength detector (ThermoSeparation Products, Riviera Beach, FL) were used. The column was perfused at 2 ml/min with 25 mM ammonium formate adjusted to pH 5.5 with formic acid. A linear gradient of the same salt to 0.5 M in 30 min and to 2 M in 60 min was imposed into the column following injection of the sample. The eluate was monitored at 280 nm and at 404 nm to detect the nitrophorincontaining fractions. Fractions were collected at 0.5-min intervals. Aliquots of the fractions (150 l) were transferred to conical polypropylene tubes containing 10 l of 1 mg/ml BSA (to prevent loss of the protein of interest by irreversible adsorption to the tubes) and dried using a SpeedVac centrifuge (Savant Instruments, Farmingdale, NY) attached to a model 1405 vacuum pump (Sargent-Welch, Skokie, IL). After the tubes were dry, 0.4 ml of water was added to each and the drying procedure repeated. Three such additions of water were needed to remove all the ammonium formate from the fractions. These dried fractions were reconstituted with 100 l of 10 mM HEPES plus 0.15 M NaCl, pH 7.4, and assayed for their inhibition of platelet aggregation as described below. Active fractions were pooled and further submitted to reverse-phase chromatography using a 4.3 ϫ 250 mm Macrosphere column (300 Å pore, octadecyl silica column) from Alltech (Deerfield, IL). A gradient from 10 to 60% acetonitrile in 0.1% trifluoroacetic acid in water at 0.5 ml/min with duration of 80 min was imposed after application of the sample. Eluates monitored at both 220 and 280 nm were collected at 1-min intervals. Aliquots of these fractions were transferred to conical 1.5-ml tubes containing 10 l of 1 mg/ml BSA and dried once as described above. These were tested for platelet aggregation inhibitory activity after reconstitution in 100 l of HS.
Protein Analysis-Amino acid analysis, mass spectrometry, and amino-terminal sequencing of the purified proteins were performed by the Harvard microchemistry facility under the direction of Dr. William Lane. Laser desorption time-of-flight mass spectrometry was performed with a Finnigan LaserMat (San José, CA). Amino-terminal sequencing of the salivary RPAI-1 used a G1000A protein sequencer (HewlettPackard, Rockville, MD) with on-line 1090 HPLC.
Cloning of C31R64 and C36R66 -A 100-l aliquot of an R. prolixus salivary cDNA library constructed in -ZAP (54) was extracted with phenol/chloroform (43, 44) to obtain a template for polymerase chain reactions (PCRs). A partial clone of C31R64 was amplified by PCR using the forward primer CCTAGYGGITGYGCIGAYGTNCA (where Y ϭ C, T, N ϭ G, C, A, T, and I ϭinosine) and T7 as the reverse primer. PCR conditions were as follows: annealing at 42°C for 1 min, extension at 72°C for 2 min, and denaturing at 95°C for 30 s, with 100 ng of template and 0.1 g of each primer in a final volume of 100 l, for a total of 30 cycles. The PCR buffer composition was 25 mM MgCl 2 , 50 mM KCl, 10 mM Tris, pH 8.3, 0.01% gelatin, 0.2 mM of each dNTP, and 1.25 units of Taq DNA polymerase (Life Technologies, Inc.). The PCR product was gel-purified (Sephaglas BandPrep kit; Amersham Pharmacia Biotech) and cloned into the pCR II vector (TA cloning kit; Invitrogen, San Diego, CA). The identity of the PCR product was confirmed by sequencing (Molecular Genetics Instrumentation Facility, University of Georgia) using the SP6 primer. For library screening, the cloned PCR product was labeled with digoxigenin by a further round of PCR using the Genius labeling kit (Roche Molecular Biochemicals) according to the manufacturer's protocol. A total of 20,000 cDNA recombinants were screened, with overnight hybridization at 65°C followed by two roomtemperature washes in 2ϫ SSC, 0.1% SDS and two washes at 65°C in 0.5ϫ SSC, 0.1% SDS. Positive clones were visualized using the nitro blue tetrazolium/X-phosphate color reaction protocol (Genius kit; Roche Molecular Biochemicals). Ten positive clones were picked, extracted in SM buffer, and screened a second time with the same probe and protocol. Clones from the second round of screening were converted to Bluescript (Stratagene, La Jolla, CA) plasmids using the manufacturer's excision protocol in Escherichia coli XL1 blue mrf Ϫ cells. Four clones were sequenced in both directions at the Molecular Genetics Instrumentation Facility. Sequence comparisons, translations, and BLAST searches were performed using the GCG software package.
Two variants of C31R64, differing in seven amino acids in the mature peptide region, were noted. The variants differed in the presence or absence of a NdeI restriction site. To determine the relative abundance of the two variants, the insert region of each of the 10 C31R64 clones was excised with EcoRI and XhoI (Life Technologies, Inc.), gel-purified (Sephaglas BandPrep kit; Amersham Pharmacia Biotech), and digested with NdeI. Restriction digest products were visualized on a 1% agarose gel.
A partial PCR-generated clone of C36R66 was isolated as described above for C31R64, using the forward primer GCNACNACIATGC-CIAARGARTG. This primer was designed for a different protein (not included in the present report), but cDNA of C36R666 was fortuitously also amplified, TA cloned, and sequenced. Subsequent procedures were as described above, with the exception that five -ZAP cDNA clones, all identical, were isolated and sequenced.
Expression of C36R66 -The cDNA for C36R66 was prepared for expression in E. coli by inserting an NdeI restriction site at the 5Ј end of the coding sequence. This was accomplished by PCR using the primer CTAGCTAGCATATGGAGGCATTCTGTGCTAACCCTCC along with a primer complementary to the T7 RNA polymerase recognition site. The reaction produced a single product of approximately 0.5 kilobase pairs. The product was purified in an agarose gel and cloned into the vector PCR2.1 (Invitrogen). After confirmation of the sequence of the insert, the modified cDNA was cut with NdeI, and XhoI was moved into the expression vector pET17B (Novagen, Madison, WI). Cultures of the resulting clone were grown in Luria broth (LB) medium at 37°C in 2.0-liter Fernbach flasks to an optical density of 0.6 -1.0, and expression of RP66 was induced by adding isopropyl-1-thio-␤-D-galactopyranoside to 0.6 mM. At the point of induction, the incubation temperature was reduced to 30°C, and the flasks were shaken at 150 rpm for 16 h.
Cells were harvested by centrifugation, washed in 40 mM Tris-HCl, pH 7.5, and resuspended in 40 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, and 0.2 mM phenylmethylsulfonyl fluoride (buffer A). The suspension was incubated with lysozyme for 30 min at room temperature and then sonicated. The lysate was centrifuged at 100,000 ϫ g at 4°C for 30 min and the supernatant collected. Analysis by SDS-PAGE showed that a large percentage of the expressed protein was in the cytoplasmic fraction of the cell extract.
Calculation of the isoelectric point of C36R66 (using the PEPTIDE-SORT module of GCG) indicated that it is quite basic (P i ϭ 10.1). Accordingly, Q-Sepharose (Fast-Flow; Amersham Pharmacia Biotech) was used to remove most of the soluble protein in the sample in a batch procedure. A slurry of Q-Sepharose (25 g) in 40 mM Tris-HCl, pH 7.5, was added to the cell supernatant. After stirring for 1 h on ice, the Q-Sepharose was removed by filtration and washed with buffer A. The filtrate was saved and the Q-Sepharose washed further with buffer A containing 0.5 M NaCl. The C36R66 peptide was contained in the initial filtrate, as determined by SDS-PAGE.
The filtrate obtained after Q-Sepharose purification was dialyzed against 40 mM sodium phosphate, pH 6.8 (buffer B), and applied to a column of SP-Sepharose (Fast-Flow, Amersham Pharmacia Biotech) equilibrated with buffer B. The column was eluted with a gradient of 0 -0.5 M NaCl buffer B. The pooled fractions containing C36R66 (as determined by SDS-PAGE) were concentrated by ultrafiltration, applied to a Sephacryl S-200 column, and eluted with 40 mM Tris-HCl, pH 7.5. Two peaks of purified C36R66 were obtained. SDS-PAGE in the absence of reducing agents suggested that the early eluting peak was due to a disulfide-linked dimer and that the second peak was a monomer. Addition of dithiothreitol (DTT) (to 1.0 mM) to the dimeric fractions resulted in a single band consistent in size with the monomeric protein.
The gel filtration fractions containing DTT and those without DTT were pooled separately and concentrated by ultrafiltration. The DTT-containing fractions were further submitted to TSK SW 2000 molecular sieving chromatography to remove contaminating DTT, which interferes in the platelet aggregation assays, performed as above.
Preparation of Human, Bovine, and Rabbit Platelets-Platelet-rich plasma (PRP) was obtained by platelet-pheresis from medication-free platelet donors at the DTM/NIH blood bank under the direction of Dr. S. Leitmann. Washed human platelets were prepared by centrifugation of PRP at room temperature as described (45) . Fresh bovine blood was obtained from NIH-Poolesville (Frederick, MD) and collected in acid/ citric/dextrose (ACD, 1:10); platelet-rich plasma was obtained by centrifugation of blood at 180 ϫ g for 10 min at room temperature. Fresh rabbit blood was obtained from Spring Valley Laboratories (Woodbine, MD), collected in heparin (0.1 units/ml), and platelet-rich plasma obtained by centrifugation of blood at 375 ϫ g for 12 min at room temperature as described (46) . Human platelet-poor plasma was obtained by centrifugation of PRP for 5 min at 14,000 ϫ g at room temperature. For platelet adhesion assays, platelet-rich plasma was incubated for 30 min at room temperature with calcein-AM (2 M) followed by washing and recovering of the cells as described above.
Platelet Aggregation Assays Using Microplate Reader-Platelet aggregation assays were performed on a Thermomax microplate reader (Molecular Devices, Menlo Park, CA) as described previously with further modifications (34) . The use of microplate assays has been shown to give quantitatively and qualitatively similar results when compared with Born aggregometry (47) . Briefly, 30 -50 l of Tyrode/BSA were mixed in 96-well flat-bottom plates (Falcon 3912; Becton Dickinson, Oxnard, CA) in the presence of the indicated agonists and reconstituted column fractions or recombinant peptide. When thrombin was used as an agonist, Gly-Pro-Arg-Pro amide (1 mM) was added to prevent clotting. Aggregation was initiated by the addition of 50 l of human platelet-rich plasma. The plate was stirred on a microplate mixer (Series 4732; Cole Palmer, Vernon Hills, IL) for 5 s before being transferred to the microplate reader, where the turbidity change at 650 nm was measured in units of absorbance every 11 s with agitation between readings. In some experiments, platelet aggregation and shape change were monitored using an Aggregometer Chrono-Log Aggregometer (Chrono-Log Co., Havertown, PA).
Inhibition of TXA 2 -mediated Platelet Responses-For inhibition of platelet cyclo-oxygenase, platelets were incubated with vehicle or indomethacin (50 M) for 30 min at room temperature in the presence of apyrase (0.25 units/ml) and EDTA (5 mM). PRP was centrifuged and washed as described above and supplemented with 30% autologous PPP. Successful inhibition of cyclo-oxygenase was demonstrated by the complete inhibition of platelet response to 500 M arachidonic acid. For TXA 2 /PGH 2 receptor blockade, PRP was incubated for 10 min with vehicle (ethanol, 0.2% v/v) or TXA 2 antagonists SQ29548 (10 M) and 8-epi-PGF 2␣ (10 M) before platelet stimulation. For platelet desensitization, platelet-rich plasma was incubated with vehicle (ethanol, 0.02% v/v) or with 2 M U46619 plus 10 M 8-epi-PGF 2␣ for 30 min at room temperature in the presence of apyrase (0.25 units/ml) and EDTA (5 mM). PRP was centrifuged and washed as described above and supplemented with 30% (v/v) autologous PPP. In the presence of indomethacin or TXA 2 /PGH 2 antagonists or TXA 2 /PGH 2 receptor-desensitized platelets, a right shift of platelet response to collagen was achieved.
cAMP Measurements-Platelets (500 l) containing 40% of plasma were incubated for 1 min with Tyrode/BSA followed by addition of Tyrode/BSA (basal) or PGE 1 (0.5 M) for 2 min. In some experiments, U46619 (0.5 M) was added to counteract PGE 1 -induced increase of cAMP, and reactions were followed for an additional 2 min. When RPAI-1 was to be tested, it was incubated for 30 s with platelets before addition of PGE 1 and U46619. Reactions were followed for 2 min as described above. An appropriate control was run in parallel. Reactions were terminated by rapid centrifugation at 10,000 ϫ g for 10 s. The supernatant was immediately removed, and then 500 l of 10% trichloroacetic acid was added, and samples were rapidly frozen in dry ice and kept frozen at Ϫ70°C overnight. After thawing, samples were sonicated 25 times at a duty cycle of 40%, and output control was set at 7 using a Branson sonifier (Danbury, CT). Trichloroacetic acid was removed by water-saturated ether extraction, and cAMP measurement was performed essentially following the manufacturer's instructions. A standard curve was performed in parallel for each donor. In all experiments, platelets were treated with indomethacin (50 M) and were unresponsive to arachidonic acid.
Isoprostane Measurements-PRP was stimulated by arachidonic acid in the presence or absence of platelet-inhibitory concentrations of RPAI-1, followed by centrifugation of the plasma for 15 s at 10,000 ϫ g. Isoprostanes were purified by Sep-Pak C-18 cartridge and detected by ELISA according to manufacturer's instructions. A standard curve was performed in parallel for each donor.
Measurement of Platelet Granule Secretion-Platelets were stimulated with U46619 and centrifuged at 10,000 ϫ g for 10 s. The supernatant was removed, cooled at 4°C, and centrifuged for 30 min at 2,000 ϫ g at 4°C. The platelet-free supernatant was diluted 1:75 and 1:150 in the kit dilution buffer and used for measurement of ␤-thromboglobulin using an ELISA kit according to the manufacturer's instructions.
Measurement of Intracellular Ca 2ϩ -Intracellular free calcium ([Ca
] i ) transients were monitored by Fura-2 fluorescence as described (45) , and fluorescence readings were recorded using a Perkin-Elmer LS-50 Fluorimeter (Beaconsfield, UK).
Intrinsic Tryptophan Fluorescence of RPAI-1-It was detected using an excitation wavelength at 280 nm and emission wavelength at 330 nm in a Perkin-Elmer LS-50B fluorimeter. Small aliquots of a stock solution of U46619 diluted in methyl acetate were added to a 1-ml solution of RPAI-1 (4.5 M) diluted in 50 mM HEPES, 0.1 M NaCl, pH 7.4. The volume of U46619 at the highest concentration used was 4%. Controls were run in parallel using methyl acetate (U46619 vehicle).
Equilibrium Dialysis-RPAI-1 was diluted in 100 l of Tyrode/BSA/ plasma to a final concentration of 4.5 M and placed in a Slide-a-lyzer mini-dialysis unit (10-kDa cut-off). This unit was placed in another tube containing [ 3 H]U46619 (0 -100 nM) diluted in Tyrode/BSA, pH 7.4, in the absence or presence of an excess of U46619 (5 M). Samples were shaken at low speed (50 rotations per min). After 2 and 12 h of dialysis at room temperature, 25 l of samples were taken from the unit, and radioactivity was counted using a 1450 Microbeta Trilux liquid scintillation counter (Wallac Co., Gaithersburg, MD). HPLC-based detection of nucleotides was done using an anion exchange TSK-DEAE column (4.5 ϫ 150 mm) obtained through Bio-Rad, perfused isocratically with 125 mM sodium phosphate adjusted to pH 3.5 with phosphoric acid.
Convulxin Purification-Convulxin was purified as described (46) . Platelet Adhesion Assays-MicroFLUOR Microtitre 96-well plates (Dynatech, Chantilly, VA) were coated with 2 g of collagen or 1.5 g of convulxin diluted in phosphate-buffered saline, pH 7.4, overnight at 4°C. Calcein-labeled platelets were added to wells for 15 min; then the plates were inverted and washed. Fluorescence was estimated using a Fluorolite 1000 microplate reader (Dynex Technologies, Chantilly, VA).
Anti-phosphotyrosine Immunoblot Assay-This was performed as described (45).
Convulxin Binding to Solubilized GPVI-Membrane preparation and convulxin binding to solubilized GPVI were performed by ligand blotting as described (50) .
Protein Concentration-This was estimated using bicinchoninic acid (BCA) protein assay reagent (Pierce), using bovine serum albumin as standard.
Statistical Analysis-Data are reported as means Ϯ S.E. The comparison between variables was analyzed by Student's t test for paired data. Significance was accepted at the p Ͻ 0.05 level.
RESULTS
One hundred pairs of homogenized and dialyzed R. prolixus were submitted to a strong cation exchange column (Fig. 1A) , and the evaporated and reconstituted fractions were tested for inhibition of collagen-induced platelet aggregation. Two sharp peaks of inhibitory activity are observed before 20 min of retention time (Fig. 1C) . These are associated with the nitrophorin fractions, as indicated by strong absorption at 404 nm in this area of the chromatogram (Fig. 1B) . These two early eluting peaks were not further studied. Two additional late eluting peaks were found. These late eluting peak fractions were combined (fractions eluting between 30.5 and 31.5 min and between 35 and 37 min), and each of the two combined fractions was further submitted to reverse-phase chromatography in an octadecyl column (Fig. 1, D and E) . Although several additional 280-nm absorbing peaks were produced by each of the two SCX column pools submitted to reverse-phase chromatography, platelet inhibitory activity was found in a few contiguous fractions in each of the two columns (Fig. 1, F and G) . These two active fractions are provisionally called C31R64 and C36R66 fractions, indicating their retention times (in min) in the cation exchange and reverse-phase columns.
By using both fractions purified by reverse-phase chromatography, we observed that, in addition to inhibiting collageninduced platelet aggregation, both inhibited arachidonic acidinduced platelet aggregation, as shown in Fig. 2 . No inhibition was found when the same fractions were tested using 20 M ADP to trigger platelet aggregation.
To characterize further the two salivary inhibitors of platelet aggregation, we submitted each to matrix-assisted laser desorption/ionization-time of flight mass spectrometry and to Edman degradation. Both fractions gave similar molecular masses of 17,292 and 17,384 for C31R64 and C36R66 compounds, respectively (not shown). Both fractions yielded a single strong signal by Edman degradation, totaling 49 amino acids for C31R64 and 50 amino acids for C36R66 (Table I) . Both sequences indicate the peptidic fragments to be related, as marked in Table I .
To obtain full sequence information on these peptides, we used the primary sequence information obtained from aminoterminal sequencing to design oligonucleotide probes for PCRbased assays. Screening of a R. prolixus salivary gland cDNA library resulted in the isolation of 10 C31R64 clones of which 4 were sequenced in both directions. Two variant clones were obtained matching the amino-terminal sequence of C31R64 and one matching the sequence for C36R66. These two sequences were named R. prolixus aggregation inhibitor 1 (RPAI-1) for C36R66 and R. prolixus aggregation inhibitor 2 (RPAI-2) for C36R44. Sequence analysis using the BLAST program of the NCBI indicated homology with the following two products (39) . The sequences of RPAI-1 and RPAI-2, as well as those of the two T. pallidipennis products, are shown in Table II. RPAI-1 was successfully expressed in E. coli, the product being confirmed by both mass spectrometry and Edman degradation (not shown). Sufficient amounts of the peptide were thus produced for further studies on the mechanism of RPAI-1 inhibition of platelet aggregation. Fig. 3A shows that in plateletrich plasma, RPAI-1 inhibits platelet aggregation induced by low concentrations of collagen. This inhibition is characterized by a slow aggregation rate (slope) and an IC 50 of ϳ200 nM. At high concentrations of collagen (Ͼ5-10 g/ml), RPAI-1 is inactive even when higher concentrations of the inhibitor are employed. RPAI-1 caused a remarkable inhibition of thromboxane A 2 analog (U46619)-and arachidonic acid-induced platelet aggregation, with IC 50 of ϳ200 -600 and 200 -400 nM, respectively (Fig. 3, B and C) . Platelet aggregation induced by other TXA 2 mimetics, U46069 and IBOP, was effectively inhibited by RPAI-1 (data not shown). Low concentrations of thrombin (Ͻ0.050 units/ml) or convulxin (Ͻ50 pM), causing 10 -20% of platelet aggregation, was attenuated by RPAI-1 and was followed by reversibility of platelet aggregation; however, at higher concentrations of both agonists, the inhibitor was without effect (Fig. 3, D and F) . Fig. 3E shows that RPAI-1 inhibits low concentrations (Ͻ1 M) of ADP-induced platelet aggregation, being devoid of activity at higher ADP concentrations (see also Fig. 7) . RPAI-1 also blocks washed platelet aggregation, although at slightly higher concentrations (data not shown). Thus, recombinant RPAI-1 is able to inhibit platelet aggregation by collagen and arachidonic acid, as did the native molecule.
Together, these results pointed to the hypothesis that RPAI-1 is an inhibitor of either the TXA 2 or ADP pathway of platelet activation. Thus, four distinct protocols were designed in an attempt to attenuate the participation of the TXA 2 and ADP pathway as a pro-aggregatory stimulus in platelet aggregation induced by collagen. These protocols are based on the demonstration that platelets stimulated by low concentrations of collagen are dependent on TXA 2 , a prostanoid recognized as the main mediator of granule secretion by this ligand (1, 2) . In the first protocol, platelets were pretreated with the cyclooxygenase inhibitor indomethacin (50 M) to inhibit production of TXA 2 . Fig. 4A shows that RPAI-1 inhibits collagen-induced platelet aggregation in control, indomethacin-free platelets but loses its inhibitory property when TXA 2 synthesis is blocked. Second, TXA 2 /PGH 2 receptor was desensitized by 30 min incubation of platelets with both U46619 and 8-epi-PGF 2␣ (52, 53) followed by washing and recovery of the cells (Fig. 4B) . RPAI-1 inhibition of collagen-stimulated platelets was confirmed using non-desensitized platelets; in contrast, inhibition of collageninduced platelet aggregation by RPAI-1 was completely abolished in desensitized cells. Third, the contributions of TXA 2 in collagen-activated platelets were avoided using a combination of two well studied TXA 2 /PGH 2 antagonists, SQ29541 and 8-epi-PGF 2␣ (52) (53) (54) . Fig. 4C shows that in the presence of antagonist vehicle (ethanol, 0.2%, v/v), RPAI-1 readily inhibited collagen-induced platelet aggregation; however, in the presence of both SQ29548 (10 M) and 8-epi-PGF2␣ (10 M), RPAI-1 inhibitory effect was diminished. Fourth, bovine platelets, whose platelet aggregations by collagen are only slightly affected by ADP receptor antagonist (ARL66096) and are irresponsive to TXA 2 /PGH 2 mimetics (55, 56) are not sensitive to RPAI-1 (Fig. 4D) . These experiments indicate that RPAI-1 could be inhibiting platelet aggregation via the TXA 2 pathway or some event following activation of the TXA 2 pathway.
In an attempt to reveal the mechanism of platelet inhibition by RPAI-1, a number of experiments were initially performed based on the RPAI-1 primary sequence. RPAI-1 has the signature (TDY) of and sequence homology to other proteins whose three-dimensional structure determines them to be members of the lipocalin family of proteins (57) . The lipocalin fold is characterized by a large cup-shaped cavity (␤-barrel) that is adapted to the binding of small ligands including arachidonic acid (57) . Because the inhibitory effect of RPAI-1 was abolished in platelets rendered hyporesponsive to TXA 2 , we attempted to ascertain whether its inhibitory effect was mediated by the binding of arachidonic acid or U46619 to RPAI-1. To that end, we tested the effects of RPAI-1 on platelets stimulated by U46619, an agonist that induces a small release of arachidonic acid in human platelets (58, 59) . The inhibitory property of RPAI-1 upon human platelet stimulation by U46619 was preserved in platelets whose residual arachidonic acid release was (0 -100 nM) to RPAI-1 (4.5 M) was attempted by equilibrium dialysis in the presence of plasma (40%), no specific increase in the radioactivity associated to RPAI-1 was observed after 2 or 12 h, when compared with the sample containing an excess of 5 M [ 3 H]U46619 (not shown). Furthermore, U46619 did not change the intrinsic RPAI-1 fluorescence when compared with U46619 vehicle (methyl acetate) (not shown). When competition binding experiments were performed in the presence of plasma (40%), we could not detect inhibition of [ 3 H]U46619-specific binding to platelets at very high concentrations of RPAI-1 (Ͻ9 M) (not shown). Taken together, these results suggest that the mechanism by which RPAI-1 blocks platelet aggregation is not related to prostaglandin or arachidonic acid-binding properties of the molecule. We then considered whether the effects of RPAI-1 could be indirect and mediated by a putative enzymatic activity of the molecule, as it is known that U46619-induced platelet aggregation is inhibited by 8-epi-PGF 2␣ (53, 54) . This possibility was strengthened by the observation that the sequence Trp 119 Ser 133 of RPAI-1 is 93% positive (14/15) and 66% identical (10/15) when compared with sequences Trp 119 -Thr 133 of prostaglandin H 2 D-isomerase precursor (NCBI accession number Q29487), a lipocalin described with enzymatic activity (57) . By using an ELISA kit for 8-iso-PGF 2␣ , we could not detect production of 8-iso-PGF 2␣ by RPAI-1 (730 M) at concentrations that entirely blocked arachidonic acid (300 M)-induced platelet aggregation (basal platelets, 22 Ϯ 0.52 pg/ml; RPAI-1, 28 Ϯ 0.89 pg/ml; arachidonic acid, 110 Ϯ 2.89 pg/ml; arachidonic acid plus RPAI-1, 90 Ϯ 2.1 pg/ml).
According to platelet aggregation assays, it was clear that inhibition of platelet aggregation by RPAI-1 was not affected by preincubation of the inhibitor with platelets or with U46619 (data not shown). This finding suggested that RPAI-1 might be affecting platelet activation at a distal point of the TP receptor. To investigate such a mechanism, platelet aggregation was studied using an aggregometer. Platelet response to U46619 is mediated by two different receptors or by the same receptor with two different affinities as follows: one binding site that binds U46619 with high affinity that mediates platelet shape change, Ca 2ϩ increase, and cortactin tyrosine phosphorylation (15) (16) (17) , and a second binding site that binds U46619 with low affinity and mediates platelet aggregation, inositol-phosphate production, and protein kinase C activation (18 -20) . Fig. 5A shows the effects of RPAI-1 on U46619-induced platelet aggregation. In control platelets, the 1st min after addition of U46619 is characterized by an initial decrease of light transmittance (shape change) that is followed by a gradual increase of light transmittance where the amplitude of the tracings almost did not vary, a pattern that is typical of small aggregate formation. At later time points, high amplitude of the tracings is observed, indicating formation of large aggregates. When RPAI-1 was added to platelets before addition of U46619, a dose-dependent attenuation of platelet-rich plasma aggregation was observed, but full inhibition has never been attained. Characteristically, formation of large aggregates was blunted. Similar results were obtained when platelets were stimulated by U46619 in the presence of apyrase and yohimbine (Fig. 5A) . Using a microplate reader for platelet aggregation assays, dose-response curves using U46619 were performed in the presence of increasing concentrations of RPAI-1. Fig. 5B shows that the inhibitory effects of RPAI-1 were surmounted at higher U46619 concentrations. Transformation of the data according to Schild plot (60) An Antiplatelet Lipocalinthat platelet shape change and Ca 2ϩ increase were not affected by RPAI-1 at platelet-inhibitory concentrations. According to ELISA for detection of ␤-thromboglobulin, a marker of ␣-granule secretion, release reaction was attenuated by RPAI-1 at platelet-inhibitory concentrations but was never completely abolished (Fig. 5D) . These results are in contrast to the effects of the low affinity TP antagonist, GR32191, that completely blocks platelet aggregation and brings platelet secretion to basal levels (52) . We concluded that the effects of RPAI-1 on platelets could not be explained by interaction with high or low affinity binding sites necessary for U46619-induced platelet activation.
Based on the data gathered in Fig. 5 , we concluded that RPAI-1 blocks a distal step of platelet aggregation triggered by U46619, possibility by affecting the pro-aggregatory function of molecules released by activated platelets, most likely ADP. It is known that ADP is an important molecule involved in U46619-induced platelet aggregation and formation of large platelet aggregates; it is also responsible for the decrease in PGE 1 -induced augmentation of intraplatelet cAMP by U46619 (20) .
In an attempt to test this hypothesis, we studied the effects of RPAI-1 on the U46619-mediated decrease of cAMP. Fig. 6A shows that RPAI-1 does not affect basal platelet cAMP. On the other hand, PGE 1 -induced cAMP accumulation, which is antagonized by U46619, is restored by RPAI-1. Next, platelets were incubated with sub-aggregating doses of ADP. Fig. 6B clearly shows that ADP dose-dependently reverses the inhibitory effect of RPAI-1.
Next, we tested RPAI-1 on ADP-mediated platelet responses. Using indomethacin-treated platelets, RPAI-1 dosedependently inhibited platelet shape change and platelet aggregation triggered by low ADP concentrations (Fig. 7) .
We tested the hypothesis that RPAI-1 could bind to ADP using large zone chromatography. In this experiment, BSA (control) or RPAI-1 was gel-filtered in a column equilibrated in buffer alone or equilibrated with ADP. Fig. 8A shows that BSA elutes as single peak at 280 nm whether the column was equilibrated with buffer or ADP. The BSA spectra were also the same in both situations (Fig. 8B) ; accordingly, the differential spectrum does not show any specific increase at ϳ260 nm, near the maximum absorbance wavelength for ADP (Fig. 8C) . Fig.  8D shows that RPAI-1 elutes as two peaks, corresponding to the monomer and the dimer of the protein, here called RPAI-1a and RPAI-1b, respectively; in both cases, an increase of absorbance at ϳ260 nm was observed when the column was equilibrated with ADP. That this change in RPAI-1 absorbance at ϳ260 nm is related to the binding of ADP to the protein is confirmed by the spectra of RPAI-1, which clearly shows an increase in the UV absorbance at ϳ260 nm (Fig. 8, E and G) . In contrast to BSA, the difference between the spectra obtained in both situations is characterized by a peak of absorbance at 264 and 263 nm for RPAI-1a and RPAI-1b, respectively (Fig. 8, F  and H) . Preliminary studies indicate that RPAI-1 is already saturated with ADP at nucleotide concentrations of 0.1 M ,   FIG. 3 . Effects of RPAI-1 on human platelet-rich plasma aggregation. Platelet-rich human plasma was stimulated by the indicated concentration of RPAI-1 in the presence of A, collagen (q, 0.5 g/ml; f, 1.25 g/ml; OE, 2.5 g/ml; , 5 g/ml); B, U46619 (q, 0.14 M; f, 0.35 M; OE, 0.7 M); C, arachidonic acid (q, 164 M; OE, 328 M); D, thrombin (OE, 0.05 units/ml; q, 0.1 units/ml; f, 0.2 units/ml); E, ADP ( , 0.25 M; , 0.5 M; q, 10 M; f, 20 M; OE, 40 M);, and F, convulxin (OE, 30 pM; q, 50 pM; f, 100 pM) in the presence of the indicated concentrations of RPAI-1. For low concentrations of ADP (Ͻ2 M), experiments were performed using an aggregometer. Platelet aggregation was monitored as described under "Experimental Procedures." Points are the mean Ϯ S.E. of experiments performed in triplicate (n ϭ 3).
indicating it to have high affinity to ADP (results not shown).
Next, we addressed the question whether RPAI-1 was working as an ADPase. Thus, RPAI-1 was incubated with ADP (or buffer, control) for different incubation times, and the samples were analyzed by fast protein liquid chromatography. Incubation of ADP (up to 90 min) with buffer alone had almost no effect on ADP concentration. However, when ADP was incubated with RPAI-1, we could detect an increase of AMP formation that was accompanied by a decrease of ADP concentration (not shown). After 90 min incubation of RPAI-1 with ADP, the nucleotide was partially (ϳ75%) hydrolyzed indicating that RPAI-1 is a nucleotide-binding molecule with very low ADPase activity.
RPAI-1 is homologous to pallidipin, a 19-kDa specific inhibitor of collagen-induced platelet aggregation isolated from T. pallidipennis. It has been suggested that pallidipin blocks the collagen platelet receptor (39) . A number of experiments were thus performed to test the effects of RPAI-1 on collagen platelet adhesion receptor (integrin ␣ 2 ␤ 1 ) and collagen platelet activation receptor (GPVI) (3, 4, 61) . According to our results, (i) RPAI-1 does not inhibit platelet adhesion to immobilized collagen or to immobilized convulxin (not shown), a specific ligand of GPVI isolated from C. durissus terrificus (50); (ii) RPAI-1 blocks low concentrations of convulxin-induced platelet aggregation; this finding is consistent with the pro-aggregatory function of ADP at low concentrations of convulxin (59); (iii) the integrin ␣ IIb ␤ 3 -independent platelet protein tyrosine phosphorylation (62) triggered by subaggregating concentrations of convulxin (Ͻ30 pM), detected as an increase in the tyrosyl phosphorylation content of a 72-kDa protein, was not affected by a 35,000 molar excess of RPAI-1 (not shown); and (iv) the interaction of Cvx with GPVI, as studied by ligand blotting, was unaffected by a 70,000 molar excess of RPAI-1 (not shown). Taken together, our results indicate that RPAI-1 does not interact with integrin ␣ 2 ␤ 1 or GPVI.
It has been shown that oxidants positively modulate platelet aggregation by a number of agonists (63) . In fact, collageninduced platelet aggregation is accompanied by H 2 O 2 production, and platelet aggregation is inhibited by catalase (63). Because RPAI-1 is fully active when platelets are stimulated by U46619 in the presence of free radical scavengers, including 1000 units/ml catalase (H 2 O 2 scavenger), 120 units/ml superoxide dismutase (O 2 scavenger), 5 mM mannitol (OH scavenger), or 5 mM ascorbic acid (antioxidant), we conclude that the inhibitory effect of RPAI-1 is not mediated by free radical scavenger properties (data not shown).
DISCUSSION
This paper describes for the first time the isolation, cloning, expression, and mechanism of action of RPAI-1, a new 19-kDa platelet aggregation inhibitor from the salivary gland of the blood-sucking bug R. prolixus. RPAI-1 has a novel and unique mechanism of action that involves inhibition of the ADP pathway of platelet activation by binding to the nucleotide. Accordingly, RPAI-1 inhibits platelet aggregation induced by low doses of ADP; it also attenuates platelet aggregation triggered by low concentrations of collagen, arachidonic acid, and thromboxane mimetic U46619. It is well known that platelet aggregation by low concentrations of these three agonists is highly dependent on ADP released from platelets; in fact, platelets treated with apyrase (64, 65) , ADP receptor antagonists (20, 66, 67) , indomethacin (that attenuates platelet secretion) (68 -70) , respond poorly to low concentrations of collagen, U46619, and arachidonic acid. In these cases, as described here for RPAI-1, platelet aggregation is characterized by a slow aggregation rate (slope) and a right-shifted dose-response curve.
Our first set of experiments suggested that RPAI-1 was affecting the TXA 2 pathway of platelet aggregation by RPAI-1 because both U46619-and arachidonic acid-induced platelet aggregation were very sensitive to RPAI-1. However, RPAI-1 does not bind to arachidonic acid or TXA 2 /PGH 2 mimetics, a property that could be expected due to its lipocalin structure. In fact, RPAI-1 was as effective at inhibiting U46619-induced control platelet aggregation as were indomethacin-treated platelets. RPAI-1 seems not to interact with the TXA 2 /PGH 2 mimetic directly according to equilibrium dialysis or binding experiments using [ 3 H]U46619, and we could not detect a change of RPAI-1 intrinsic tryptophan fluorescence by U46619. Likewise, longer incubation time of RPAI-1 with U46619 did not affect the inhibitory effects of the molecule. It is concluded that RPAI-1 does not interact with arachidonic acid or U46619. The finding that the inhibitory effect of RPAI-1 occurs seconds before addition of U46619 to platelets and is not increased by longer incubation time suggested that the molecule was not operating inducing desensitization of the thromboxane A 2 receptor (71) or any other receptor.
We next examined, by means of binding and pharmacological assays, the possibility that RPAI-1 was working as an antagonist of the thromboxane A 2 (TP) receptor. A number of studies have shown that either TXA 2 has two distinct TP receptors on platelets or, alternatively, two different affinity states of the same receptor may exist as follows: one of high affinity that mediates platelet shape change, Ca 2ϩ mobilization, and cortactin tyrosyl phosphorylation, and a second of low affinity that mediates PKC activation and platelet aggregation (15) (16) (17) (18) (19) 72) . Because U46619-induced platelet shape change and calcium increase was preserved by RPAI-1, it was clear that the high affinity TP receptor on platelet membrane was not the target of RPAI-1. Although RPAI-1 attenuates platelet aggregation, a process dependent on the low affinity receptor, it is evident from Fig. 5A that platelet aggregation took place and, according to both visual inspection of the samples and tracings of platelet aggregation, formation of small aggregates was typically found, but formation of large aggregates was reproducibly and consistently abrogated. In some experiments, inhibition of platelet function by RPAI-1 was accompanied by a tendency for disaggregation, leading to reversibility of platelet aggregation. This finding, together with the lack of inhibition of [ aggregation by TXA 2 mimetics. These results suggest that the ADP pathway of platelet activation could somehow be the target of RPAI-1, and a number of results corroborated this view as follows: (i) addition of apyrase and yohimbine did not increase the platelet inhibitory effect of RPAI-1; (ii) RPAI-1 completely blocked the U46619-mediated decrease of PGE 1 -induced augmentation of cAMP, a phenomenon largely dependent on ADP (20) ; (iii) inhibition of U46619-induced platelet aggregation by RPAI-1 has been reversed by ADP; (iv) low concentration of ADP-induced shape change and platelet aggregation were blunted by RPAI-1; (v) platelets rendered hyporesponsive to TXA 2 , which are known to have impaired secretion when the agonist is collagen (68, 69) , are slightly or not inhibited by RPAI-1; and (vi) a number of studies have demonstrated that ADP is a key molecule necessary for the formation of large aggregates (77, 78) . The molecular basis for this phenomenon has recently been characterized. Pro-aggregating molecules such as ADP have receptors coupled to G i that lower intra-platelet cAMP concentration, a negative modulator of integrin ␣ IIb ␤ 3 activation (1, 14) . Integrin ␣ IIb ␤ 3 is essential for full platelet activation because (i) it is the receptor for fibrinogen, which works as a bridge between two activated platelets, leading to the formation of platelet aggregates (1, 2), and (ii) fibrinogen binding to platelets activates a number of "outside-in" biochemical reactions that lead to the stabilization and irreversibility of platelet aggregation, in addition to potentiation of secretion (79, 80) . Thus, it is not surprising that RPAI-1 inhibition of ADP-dependent platelet aggregation by U46619 is accompanied by partial inhibition of U46619-induced platelet secretion, a finding that has been described for apyrase (81) , for ADP receptor antagonists (20, 66) , for patients with secretion defect (17) , and for patients lacking ADP receptor (82) .
Next, the mechanism of inhibition of the ADP pathway was considered. Because RPAI-1 is a lipocalin, we attempted to detect direct binding of ADP to RPAI-1. By using large zone chromatography where the column was equilibrated with ADP, we found that the spectrum of RPAI-1 changes in the presence of the nucleotide; when a differential spectra is performed a peak of absorbance at ϳ260 nm, which is close to the optimum wavelength for detection of ADP, is observed. We could also detect low ADPase activity in RPAI-1 using HPLC for detection of the conversion of ADP to AMP. This low level of activity cannot be detected by measuring free phosphate according to the method described by Fiske and SubbaRow (83) and could only be detected by fast protein liquid chromatography using an appropriate column. Our results provide definitive and unambiguous evidence that RPAI-1 is a nucleotide-binding protein with a residual apyrase activity. The physiologic role of this high affinity nucleotide-binding protein is also striking and was characterized herein, by a number of assays, as a negative modulator of platelet aggregation. Indeed, ADP at low concentrations is not a platelet aggregation per se, but it is a potentiator of platelet aggregation by many agonists. Low concentration of ADP is also reached in vitro after stimulation with many agonists, including U46619. Thus, a molecule such as RPAI-1, which scavenges low concentrations of ADP, can be regarded as an effective inhibitor of platelet aggregation. It should be emphasized that the effects of RPAI-1 were remarkable when U46619 or arachidonic acid were used, because the TP receptor, unlike the thrombin and ADP receptors, does not directly activate G i or physically associate with G i in platelets (84) . Accordingly, the cAMP lowering activity of TXA 2 is indirect and fully dependent on granule secretion, making this step of platelet activation absolutely necessary for full platelet activation and large aggregate formation by U46619 (20) . The finding that the slope of collagen-induced platelet aggregation is characteristically reduced by RPAI-1, with slight or no attenuation of the maximum aggregation obtained, and that higher collagen concentrations surmount RPAI-1 inhibitory effects is consistent with the proposal that RPAI-1 exerts its effects via the ADP-binding property of the molecule. In other words, when RPAI-1 is saturated with ADP so that it can no longer work as a buffer (a situation that occurs when higher collagen (or U46619) concentrations are employed), the concentration of free ADP progressively increases, and it starts to exert its pro-aggregatory function, with subsequent platelet aggregation. Not surprisingly, high concentrations (Ͼ15-20 g/ml) of collagen-induced platelet aggregation are not inhibited by RPAI-1 even at higher concentrations of the inhibitor because, at such concentrations, collagen-mediated platelet aggregation occurs via a protein tyrosine kinase-dependent pathway of phospholipase C␥2 activation that is independent of granule secretion (61) . Finally, it is worthy noting that an ADP-binding protein can work as a competitive inhibitor of TXA 2 -induced platelet aggregation, without interference with TP receptor, a finding that can lead to misinterpretation of the mechanism of action of some molecules.
The selection of an ADP-binding protein is particularly useful for the feeding necessities of the bug, because most platelet pro-potentiating activity of ADP is lost. Actually, the key role of ADP in hemostasis has been confirmed by apyrase knockout mice and by patients lacking ADP receptors or clopidogreltreated platelets whose platelets do not aggregate (13, 14, 25, 83) . Finally, our observation that RPAI-1 activity inhibits collagen (in addition to arachidonic acid-and U46619-induced platelet aggregation) distinguishes RPAI-1 from the homologue pallidipin, isolated from T. pallidipennis. Pallidipin has been claimed to be a specific inhibitor of receptor-mediated collageninduced platelet aggregation, although it does not inhibit shape change (39, 85 ). In the experiments described here, we show by various approaches that RPAI-1 is an inhibitor of neither the collagen adhesion receptor, integrin ␣ 2 ␤ 1 (3), nor the collagen activation receptor, GPVI (4). RPAI-1 is also distinct from the non-homologous calin, a direct collagen inhibitor from the leech Hirudo medicinalis (31) . On the other hand, the effects of RPAI-1 on platelet aggregation resembles, in some aspects, the effects of moubatin, a 17-kDa molecule from the tick Ornithodorus moubata, that was initially characterized as a selective inhibitor of collagen-induced platelet aggregation (40, 86) . Similar to RPAI-1, moubatin is an inhibitor of collagen-induced platelet aggregation, and at higher concentrations it also attenuates platelet aggregation by low concentrations of ADP or U46619. In contrast to RPAI-1, it inhibits [ 3 H]SQ29541 binding to platelets; its activity is drastically affected by plasma, and we could not detect any lipocalin signature sequences in moubatin, according to a search performed at BLOCKS data base for motif libraries for protein sequences (87) . Thus, it remains to be determined if moubatin and other similar inhibitors directly bind ADP. In conclusion, we describe here for the first time the purification, cloning, expression, and mechanism of action of RPAI-1, a new platelet aggregation inhibitor from R. prolixus that affects platelet function by a novel mechanism, binding to ADP. RPAI-1 is the only lipocalin described to date that binds ADP.
